Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SAVR Aspirin

PreclinicalSmall molecule

TThe Cleveland Clinic

SAVR Aspirin is one of 2 small molecule programs targeting Transcatheter Aortic Valve Replacement. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transcatheter Aortic Valve ReplacementTerminated

Transcatheter Aortic Valve ReplacementPreclinical

Terminated

Competition

Competitive Landscape

2 competitors in Transcatheter Aortic Valve Replacement

#DrugCompanyPhaseTrials

Angiotensin Receptor Blocker

NNational University of Ireland, Galway, Ireland

SAVR Aspirin

TThe Cleveland Clinic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transcatheter Aortic Valve Replacement1 trial

Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.

Terminated·TThe Cleveland Clinic·N/A·NCT02696226·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SAVR Aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAVR Aspirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAVR Aspirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cleveland Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Cleveland Clinic

Related News